# Title
Selective O
screening O
for O
fatty B-Disease
acid I-Disease
oxidation I-Disease
disorders I-Disease
by O
tandem O
mass O
spectrometry: O
difficulties O
in O
practical O
discrimination. O

# Abstract
In O
a O
selective O
screening O
for O
fatty B-Disease
acid I-Disease
oxidation I-Disease
disorders I-Disease
by O
tandem O
mass O
spectrometry, O
we O
tested O
the O
diagnostic O
ratios O
and O
acylcarnitine B-Chemical
concentrations O
in O
sera O
or O
blood O
spots, O
which O
were O
reported O
to O
be O
specific O
to O
very B-Disease
long-chain I-Disease
acyl I-Disease
CoA I-Disease
dehydrogenase I-Disease
deficiency, I-Disease
carnitine B-Disease
palmitoyltransferase I-Disease
I I-Disease
deficiency, I-Disease
and O
carnitine B-Disease
palmitoyltransferase I-Disease
II I-Disease
deficiency. I-Disease
While O
the O
acylcarnitine B-Chemical
profiles O
in O
the O
majority O
of O
these O
patients B-Species
were O
typical O
in O
the O
respective O
disorders, O
some O
overlapping O
of O
the O
indices O
was O
observed O
between O
these O
patients B-Species
and O
the O
infants, B-Species
who O
showed O
symptoms O
mainly O
related O
to O
hypoglycemia B-Disease
but O
did O
not O
have O
the O
disorders O
mentioned O
above. O
Although O
the O
diagnostic O
ratio O
of O
tetradecenoylcarnitine B-Chemical
to O
dodecanoylcarnitine B-Chemical
for O
very B-Disease
long-chain I-Disease
acyl I-Disease
CoA I-Disease
dehydrogenase I-Disease
deficiency I-Disease
seemed O
to O
minimize O
the O
overlapping O
in O
this O
study, O
additional O
measures O
including O
careful O
assessment O
of O
clinical O
data O
and O
enzyme O
assays O
may O
be O
necessary O
for O
the O
diagnosis O
in O
atypical O
cases. O